Archives
-
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-09-03
The reference study identifies ALDOB K87 lactylation as a metabolic and mitochondrial control point in pulmonary hypertension. Using lactylomic profiling, human pulmonary artery smooth muscle cells, rodent models, and genetic or pharmacological perturbation, the authors connect lactate accumulation to DRP1-dependent mitochondrial fission and pathological vascular remodeling.
-
QNZ (EVP4593): NF-κB Research Guide
2026-09-02
QNZ, also called EVP4593, is a quinazoline derivative that inhibits NF-κB pathway activity in cellular assays. Its reported nanomolar benchmarks support research on inflammatory signaling and Huntington’s disease models, but they do not establish clinical efficacy or direct target binding.
-
PTEN mRNA: From Mechanism to Melanoma Translation
2026-09-02
PTEN mRNA is moving from a molecular biology tool toward a translational strategy for restoring tumor suppressor function. This article examines the PI3K/Akt signaling pathway, Cap 1 and poly(A) design, delivery choices, and how EZ Cap™ Human PTEN mRNA can support rigorous cancer research and gene therapy research workflows.
-
Dlin-MC3-DMA LNP Workflow and Troubleshooting
2026-09-01
Build more reproducible siRNA and mRNA nanoparticles with Dlin-MC3-DMA, an ionizable cationic liposome lipid designed for pH-dependent endosomal escape. This workflow connects formulation control, hepatic gene silencing benchmarks, and machine-learning-guided optimization while separating validated findings from practical starting conditions.
-
Nystatin (Fungicidin) Assay Workflows
2026-09-01
Build reproducible Candida susceptibility, adhesion, and cell-based assays with Nystatin (Fungicidin), while using its distinct membrane activity as a mechanistic control. The workflow also shows why Nystatin should not be interpreted as an entry-pathway inhibitor in Spiroplasma-infected Drosophila S2 cells.
-
Mifepristone (RU486): Receptor Context in Cancer Assays
2026-08-31
Mifepristone (RU486) is more than a progesterone receptor blocker: its assay meaning depends on receptor context, tissue biology, and orthogonal validation. This guide connects cancer and reproductive readouts with a 2025 study revealing why nuclear-receptor effects can diverge between tissues.
-
Phebestin: A Nanomolar Antiplasmodial Inhibitor
2026-08-31
The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a nanomolar inhibitor of both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. By combining phenotypic, stage-specific, washout, computational, and mouse studies, it provides a coherent early assessment of aminopeptidases as antimalarial targets while also defining the evidence still needed for translation.
-
Nystatin (Fungicidin): Assay Workflows & Optimization
2026-08-30
Nystatin (Fungicidin) gives researchers a practical ergosterol-targeted tool for Candida growth, adhesion, and formulation studies. This workflow connects direct antifungal testing with nanoparticle uptake experiments while separating product-backed evidence from assay-development recommendations.
-
MLN4924 HCl Salt: NAE Inhibition Workflows
2026-08-29
MLN4924 HCl salt provides a fast pharmacological route to interrogate NAE activity, cullin-RING ligase function, protein turnover, and regulated cell death. This workflow-oriented guide connects pathway validation in cancer biology research with a mechanistic assay strategy inspired by viral RIPK3 degradation studies.
-
ACE2–MasR–Sirt1 Signaling in Septic Cardiomyopathy
2026-08-28
A February 2024 study links ACE2 downregulation with septic cardiomyopathy and shows that pharmacological ACE2 activation can improve cardiac injury in a mouse model. Its central contribution is the proposed ACE2–MasR–Sirt1 pathway, which connects renin–angiotensin signaling with mitochondrial biogenesis, inflammation, oxidative stress, and cardiomyocyte apoptosis.
-
L-Glutathione Reduced in Redox Assays
2026-08-28
Learn how L-Glutathione Reduced supports reproducible oxidative-stress, PDAC metabolism, and GST-affinity workflows without adding ethanol or DMSO to aqueous assays. This practical guide combines reference-backed interpretation with executable preparation, dosing, elution, and troubleshooting strategies.
-
HCAR3 Structures Reveal Acifran Ligand Selectivity
2026-08-27
The 2025 PLOS Biology study combines cryo-EM structures and cAMP assays to explain how HCAR3 recognizes selective agonists and differs from HCAR2. Its analysis identifies orthosteric-pocket architecture and specific residue substitutions that may guide HCAR3-directed ligand design while limiting HCAR2-associated flushing.
-
BMX-IN-1 Workflows for Infection and Cancer
2026-08-27
BMX-IN-1 is a selective, irreversible BMX kinase inhibitor for connecting host-pathogen signaling with cancer-cell phenotypes. This practical guide translates BMX-dependent lysosomal acidification findings into assay-ready workflows, controls, and troubleshooting strategies for macrophage infection and oncology research.
-
Bay 11-7821 in NF-κB Inflammation Assays
2026-08-26
Bay 11-7821 (BAY 11-7082) helps researchers connect pathogen-triggered cytokine release with downstream NF-κB activity, while also supporting apoptosis and cancer-focused experiments. This guide combines a monocyte inflammation workflow with dose planning, controls, and troubleshooting for more interpretable IKK inhibition studies.
-
N3-kethoxal for RNA and DNA Structure Mapping
2026-08-26
N3-kethoxal combines guanine-selective nucleic acid probing with an azide handle for downstream click capture. This article presents practical workflows for RNA structure mapping, accessible-DNA analysis, and RNA–protein proximity studies, with controls and troubleshooting guidance for both purified samples and cells.